Page last updated: 2024-09-05

dofequidar and Breast Neoplasms

dofequidar has been researched along with Breast Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nishikawsa, K; Saeki, T; Sato, W; Tsuruo, T1
Aogi, K; Asaga, T; Ikeda, T; Ito, Y; Kobayashi, T; Minami, H; Noguchi, S; Nomizu, T; Ohashi, Y; Saeki, T; Sato, W; Toi, M; Tsuruo, T; Yamamoto, N1

Trials

1 trial(s) available for dofequidar and Breast Neoplasms

ArticleYear
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-01, Volume: 25, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Quinolines; Treatment Outcome

2007

Other Studies

1 other study(ies) available for dofequidar and Breast Neoplasms

ArticleYear
Drug resistance in chemotherapy for breast cancer.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56 Suppl 1

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Clinical Trials as Topic; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Mice; Quinolines; Randomized Controlled Trials as Topic

2005